IVERIC bio Inc (ISEE) Stock News
NASDAQ:ISEE - Nasdaq - US46583P1021 - Common Stock - Currency: USD
ISEE Latest News, Press Relases and Analysis
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.
Astellas Completes Acquisition of Iveric Bio
/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that it has successfully completed the...
From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs
Goldman Sachs compiled research suggesting the global pharmaceutical sector has approximately $700 billion available for M&A and investments. This significant financial reserve will be crucial as patents for some of the industry's blockbuster drugs are on the expiration cliff.
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Iveric Bio stock ticks higher as it sees sale to Astellas closing July 11
Iveric Bio (ISEE) ticked up 0.8% in after hours trading after saying it expects its sale to Astellas (ALPMF) to close on July 11
Iveric Bio shares fall amid concern about Astellas deal (NASDAQ:ISEE)
Iveric Bio (ISEE), which agreed to be acquired by Astellas Pharmaceuticals (ALPMF) in May for $5.9 billion, dropped as much as 8.8%, though it has now pared the loss to 3%
Iveric Bio shares gain after HSR waiting period for Astellas deal expires
Iveric Bio (ISEE) rose 2.2% after the HSR waiting period for its planned sale to Astellas Pharmaceuticals (ALPMY) expired
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SYNH, DM, TESS, ISEE
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER ALERT: Weiss Law Investigates IVERIC bio, Inc.
/PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of IVERIC bio, Inc....
Iveric Bio gains after holder vote on Astellas takeover set for July 6 (NASDAQ:ISEE)
Iveric Bio (ISEE) rose 2% after the shareholder vote for its planned sale to Astellas Pharmaceuticals (ALPMY) was set for July 6. The July 6 date was disclosed in a proxy filing earlier...
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue.
Why Shares of Annexon Are Plummeting Thursday
Mixed trial results on a geographic atrophy eye drug led investors to sell the biotech stock.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ARNC, HMPT, ISEE, CHRA
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MDWT, ARNC, ISEE, CHRA
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ISEE, MDWT, RXDX, UNVR
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today
These three biotech stocks were on the volatile side today.
Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma
The company is working on a treatment for the eye disease known as geographic atrophy.
Mentions: APLS
Apellis weakness on Iveric Bio takeout is buying opportunity - analyst
Apellis Pharmaceuticals (APLS) stock weakness, down 7.1% in premarket trading, is a buying opportunity after competitor Iveric Bio (ISEE) agreed to be sold to Astellas Pharma (ALPMF)...
Mentions: APLS
Apelliis weakness on Iveric Bio takeout is buying opportunity - analyst (NASDAQ:APLS)
Apellis Pharmaceuticals (APLS) stock weakness, down 7.1% in premarket trading, is a buying opportunity after competitor Iveric Bio (ISEE) agreed to be sold to Astellas Pharma (ALPMF)...
Mentions: APLS
